TER-1754

**TER-1754** is an investigational, orally bioavailable small-molecule inhibitor that selectively targets **AKT1** (also known as Protein kinase B alpha), a key kinase in the PI3K/AKT pathway implicated in vascular overgrowth disorders. Developed by **Terremoto Biosciences**, it is designed for the treatment of **Hereditary Hemorrhagic Telangiectasia (HHT)**, a genetic disease characterized by arteriovenous malformations (AVMs) leading to recurrent epistaxis, anemia, and organ dysfunction. In preclinical models, TER-1754 completely prevented AVM development by maximizing AKT1 inhibition while sparing AKT2 and AKT3 to avoid toxicities like hyperglycemia, rash, or diarrhea seen with pan-AKT inhibitors, enabling potential chronic use.[1]